1 *Type of the Paper (Article)*

7

10 11

14

15

16

17

18

19

20

21

22

23

24

25

26

27 28

30

31

32

33

34

35

36

37

38

39

40

41

42

43

- Dose-dependent increase in unconjugated cinnamic 2
- acid concentration in plasma following consumption 3
- of polyphenol rich curry in the Polyspice study 4
- 5 Sumanto Haldar^{1,¶}, Sze Han Lee^{2,¶}, Jun Jie Tan², Siok Ching Chia¹, Christiani Jeyakumar Henry^{1,3,*}, 6 Eric Chun Yong Chan^{1,2,*}
 - ¹ Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research, Singapore, Singapore
- 89 ² Department of Pharmacy, National University of Singapore, Singapore
 - ³ Department of Biochemistry, National University of Singapore, Singapore, Singapore
 - [¶] Dr. S. Haldar and S. H. Lee contributed equally to this work
- 12 * Correspondence: eric.chan@nus.edu.sg; Tel: +65-65166137 13 jeya_henry@sics.a-star.edu.sg; Tel.: +65-64070793

Abstract: Spices rich in polyphenols are metabolized to a convergent group of phenolic acids. We conducted a dose-exposure nutrikinetic study to investigate associations between mixed spices intake and plasma concentrations of selected, unconjugated phenolic acids. In a randomized crossover study, 20 Chinese males consumed a curry meal containing 0 g, 6 g, and 12 g of mixed spices. Postprandial blood was drawn up to 7 h at regular intervals and plasma phenolic acids were quantified via LC-MS/MS. Cinnamic acid (CNA, p<0.0001) and phenylacetic acid (PAA, p<0.0005) concentrations were significantly increased with mixed spices consumption, although none of the other measured phenolic acids differ significantly between treatments. CNA displayed a high dose-exposure association (R2>0.8, p<0.0001). The adjusted mean AUC_{0-7 h} for CNA during the 3 increasing doses were 8.4 ± 3.4, 376.1 ± 104.7 and 875.7 ± 291.9 nM.h respectively. Plasma CNA concentration may be used as a biomarker of spice intake.

Keywords: Spices, polyphenol, phenolic acids, metabolites, nutrikinetics

29 1. Introduction

There is an increasing interest in the health effects of spices, which are widely used throughout Asia and the world to impart flavor, color and aroma within the Asian cuisine. Spices have also been utilized as therapeutic applications both within the Indian Ayurveda and in Traditional Chinese Medicines over generations. The benefits of spice consumption to human health are thought to arise due to their high polyphenol contents, including several flavonoids, lignans and phenolic acids [1,2]. In recent times, there has been an overwhelming epidemiological evidence supporting the association of dietary polyphenol intake with the risk reduction of several chronic diseases, including type 2 diabetes, cardiovascular diseases, neurodegenerative diseases, and some cancers. and the elucidation of specific bioactive phytochemicals responsible for these beneficial effects is paramount in understanding the mechanisms for their protective effects. While parent polyphenols often display desirable effects in vitro, their relevance is somewhat limited in vivo, given their low oral bioavailability and low systemic concentrations [3]. On the other hand, bioactive metabolites derived from the extensive in vivo biotransformation of dietary polyphenols may exhibit higher systemic exposure, but often display large interindividual differences [4]. It is therefore pertinent to conduct bioavailability

studies [5], in a real life dietary context, to characterize the systemic exposure of polyphenolic metabolites so as to elucidate the biological effects of the parent polyphenols [1].

Several authors have provided extensive overviews on the metabolic fate of plant polyphenols upon consumption in human diet [6–8]. In summary, dietary polyphenols are consumed as glycosides which are hydrolyzed to their aglycone metabolites in the small intestine prior to absorption. They may eventually be conjugated to form methyl/sulfate/glucuronide metabolites in the liver prior to their systemic absorption and disposition. However, glycosides that are incompletely absorbed in the small intestine can transit to the large intestine, where they are metabolized by the microflora in the colon. A diverse group of dietary polyphenols and their metabolites are catabolized into a relatively small number of terminal metabolites, principally phenolic acids. Therefore, the systemic exposures of dietary parent polyphenols are often limited [9,10]. Consequently, the quantity and identities of downstream metabolites of dietary polyphenols are relatively similar irrespective of the dietary source of polyphenols [11]. Therefore, studies exploring bioefficacy of polyphenols need to take this fact into account [12].

Phenolic acids are one of the major byproducts of the metabolism of several polyphenols. While foods such as fruits, vegetables, tea and coffee are important sources of dietary phenolic acids in the Western diet [13], several spices and base vegetables such as ginger, onions etc. used in curries are also rich sources of phenolic acids [2] within an Asian dietary context. Given that phenolic acids per se are highly bioavailable [14], these compounds may in fact be largely responsible the beneficial effects seen with consumption of spices [15,16]. However, to our best knowledge, there have been no randomized controlled dose-response trial that has specifically investigated the bioavailability of phenolic acids from dietary doses of mixed spices, as normally eaten in curries.

We have recently undertaken the Polyspice Study which found significant improvements in glucose homeostasis in response to increasing intake of polyphenol rich curry made with 7 mixed spices and 4 base vegetables [17] as well as observing dose-dependent increases in postprandial plasma GLP-1 concentration [18]. Given that phenolic acids and/or their derivatives in systemic circulation have been shown to modulate glucose homeostasis [19] as well as increase postprandial GLP-1 response [20], the primary aim of this present study was to further investigate whether the dose-dependent increases in the consumption of polyphenol rich mixed spices and base vegetables can lead to increases in plasma concentrations of a panel of phenolic acids. The panel of phenolic acids chosen for analyses were based on the native phenolic acids present in the test meal ingredients [2], as well as by predicting the metabolic fate of the parent polyphenols (e.g. various flavonoids, phenolic acids, lignans, and curcuminoids) present in these ingredients. The potential pathways for metabolism of parent polyphenols are outlined into a metabolic map (Figure S1) [8,21]. Given their diversity, not all polyphenols would be metabolized via the outlined metabolic pathways, although, we hypothesized that substantial proportion of parent polyphenols present in the fed meal would be metabolized into a small panel of terminal phenolic acids metabolites, plasma concentrations of which would vary according to the amounts of polyphenol consumed. Furthermore, the secondary aim of this study was to establish the plasma nutrikinetic profiles of the measured phenolic acids in response to spice consumption at different doses. The findings of this study should therefore inform future dose-exposure-effect studies with spices and/or other polyphenol rich foods.

2. Materials and Methods

86 2.1 Study design

The detailed methods for this Polyspice study have been described elsewhere [17]. In brief, this was a three-way randomized, controlled, crossover, acute feeding trial in healthy Chinese males (age 23.7 ± 2.30 y, BMI 23.0 ± 2.31 kg/m²). Three days prior to the main test day, each volunteer avoided

vigorous physical activity and adopted a low polyphenol diet. On the main test day, the volunteers arrived at the study centre in the morning, after an overnight fasting period of a minimum of 10 hours. On each of 3 test sessions, the volunteers consumed in random order 1 of 3 test meals: Dose 0 Control (D0C), Dose 1 Curry (D1C) and Dose 2 Curry (D2C). D0C, D1C, and D2C contained 0 g, 6 g, and 12 g mixed spices respectively. The mixed spices were prepared by thoroughly mixing dried powders of 7 different spices consisting of turmeric (Everest, India), coriander seeds (Everest, India), cumin seeds (Everest Spices, India), dried Indian gooseberry ('amla', emblica officinalis, Ramdev Spices, India), cayenne pepper (Robertson's, South Africa), cinnamon (McCormick's, USA), and clove (Robertson's, South Africa) in the ratio of 8:4:4:4:2:1:1 respectively. The 'base vegetables' used in the curry recipes consisted of tomatoes, onions, ginger, and garlic in the ratio of 5:2:1:1, with D0C, D1C and D2C containing 0 g, 90 g, and 180 g base vegetables respectively. The 3 test meals were matched for total vegetable content by including 130 g peeled eggplant (Solanum melongena) and 50 g tomatoes to DOC and 90 g peeled eggplant to D1C. Plain white rice was consumed along with each test mealand the composition of all 3 test meals were isocaloric and macronutrients matched. A standardized lunch was served after the 3 h postprandial blood draw time point, consisting of a made-to-order chicken lasagna (TopChoice Food Industries (S) Pte Ltd., Singapore), which specifically excluded polyphenol-rich ingredients such as black pepper, herbs, spices, onion, garlic or ginger from the product's original recipe There was a minimum of 1-week washout period between each session.

The study was approved by the Domain Specific Review Board in Singapore (ref: C/2015/00729), registered at ClinicalTrial.gov (ref: NCT02599272) and was conducted in accordance with the Declaration of Helsinki and the Singapore Good Clinical Practice (GCP) guidelines. All participants provided written informed consent. In total, 17 volunteers completed all three study sessions while the remaining 3 volunteers only undertook D0C and D2 sessions.

2.2 Total Polyphenol Content (TPC) of Test Meals

The TPC of the prepared test meals were analyzed using the Folin-Ciocalteu assay and expressed in gallic acid equivalents (GAE) as described previously [17]. The TPC (mean \pm SD) per portion (without rice) were 130 \pm 18.7 mg GAE, 556 \pm 19.7 mg GAE and 1113 \pm 211.6 mg GAE for D0C, D1C, and D2C respectively.

2.3 Blood Sample Collection

Venous blood was collected into 6 mL BD Vacutainer® Plus Plastic K_2 EDTA tubes at baseline prior to test meal consumption (0 h) followed by 12 postprandial time points at regular intervals: 0.5 h, 1.0 h, 1.5 h, 2.0 h, 2.5 h, 3.0 h, 3.5 h, 4.0 h, 4.5 h, 5 h, 6 h, and 7 h. The plasma sample was centrifuged at 1,500 g for 10 min at 4°C within 45 min of collection. Aliquots were stored at -80°C until analysis.

2.4 Plasma Phenolic Acids Analyses

The panel of phenolic acids chosen for analyses were based on the predicted metabolic fate of polyphenols contained within the ingredients used in our test meals, as described above. The selected phenolic acids and their sources were as follows: 3-hydroxyphenylpropanoic acid (3OH-PPA), 3-hydroxyhippuric acid (3OH-HA) and 4-hydroxyhippuric acid (4OH-HA) were purchased from Carbosynth (Berkshire, UK); benzoate-d5 (BA-d5) from Cambridge Isotope Laboratories (Andover, MA); 4-hydroxyphenylpropanoic acid (4OH-PPA), phenylpropanoic acid (PPA), cinnamic acid (CNA), 3-hydroxybenzoic acid (3OH-BA), 4-hydroxybenzoic acid (4OH-BA), benzoic acid (BA), hippuric acid (HA), phenylacetic acid (PAA), 3-hydroxyphenylacetic acid (3OH-PAA), 4-hydroxyphenylacetic acid (4OH-PAA), gallic acid, and Folin-Ciocalteu reagent from Sigma-Aldrich (St. Louis, MO); acetic acid from Merck (Darmstadt, FRG). Ultra-pure water from Adrona (Rīga,

Latvija) was used. Unless otherwise stated, all chemicals and reagents were obtained from Sigma-Aldrich (St. Louis, MO).

Stock solutions of 10 mM of each analyte were prepared in acetonitrile. Baseline (0 h) plasma was pooled from all participants and used as a matrix in equal volume for each calibration standard. BA, 3OH-BA, 4OH-BA, 3OH-PPA, 4OH-PPA, 3OH-HA, 4OH-HA, CNA were diluted to calibration concentrations of 5-1000 nM, while PAA, 3OH-PAA, 4OH-PAA, PPA, HA were diluted to concentrations of 25-5000 nM. All standard solutions were freshly prepared and kept in -20 °C prior to

2.5 UHPLC-MS/MS analysis

use.

Protein precipitation was undertaken using 400 μ L acetonitrile containing 1 μ M of BA-d5 internal standard was added to 100 μ L of plasma, calibration, quality control or blank samples. The sample was centrifuged at 16,000 g for 15 min at 4°C. 400 μ L of the supernatant was recovered and evaporated under a nitrogen flow. Finally, extracts were reconstituted with 80 μ L of 90% mobile phase A and 10% mobile phase B.

The detection of plasma phenolic acids was performed on an Agilent Infinity 1290 Liquid Chromatography System (Agilent, United States) (UHPLC) coupled to a SCIEX Triple Quad 3500 mass spectrometry (SCIEX, USA) (MS). 5 μ L of reconstitute was injected in an ACQUITY UPLC C18 column, 2.1 × 100 mm, 1.7 μ m (ACQUITY, Waters, USA) with an ACQUITY UPLC BEH C18 guard column, 2.1 × 5 mm, 1.7 μ m (ACQUITY, Waters, USA). The mobile phase consisted of 0.01% acetic acid (solvent A) and acetonitrile with 0.01% acetic acid (solvent B). The elution profile (flow rate of 0.5 mL/min) started at 10% solvent B and was increased linearly from 10% to 75% between 0.5 to 3.5 min and to 100% at 3.5 min at which percentage of solvent B was held constant for 1 min. The gradient was reverted to 10% solvent B for 1 min for equilibration. Electrospray ionization was performed in the negative ionization mode (ESI-) with gas temperature 500°C, curtain gas 30 psi, collision gas 7 psi, ion source gas 1 60 psi, ion source gas 2 60 psi and capillary voltage -4500 V. The multiple reaction monitoring (MRM) conditions for each analyte were determined by direct infusion into the MS. MultiQuant software 3.0.2 was used to analyze the data. Optimized MS component-dependent parameters are summarized in Table S1. As analytes are endogenous in nature, quantification was performed via method of background subtraction [22]. Accuracy and precision of the quantification are reported in Table S1.

2.6 Statistical Analyses

168

169

170

171

172

173

174

175

176

177 178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196 197

198

199

200

201

202

203

204

205

206

The maximum concentration in plasma (Cmax), time needed to reach Cmax (Tmax), and area under the plasma concentration-time curve until 7 h (AUC_{0-7 h}) were calculated using Phoenix WinNonlin 6.3 (Certara, USA). Mean AUC_{0-7 h} and C_{max} was normalized against the basal levels of each individual to account for differences in inter-individual baseline plasma concentrations of the metabolites. The normalized data was evaluated for statistical differences using repeated measures one-way ANOVA analysis with post-hoc Bonferroni's correction. Linear regression analysis between TPC of each meal and AUC₀₋₇ h was further performed. Dose-dependent linear correlation coefficients (R2) were determined using GraphPad Prism 6.

As CNA displayed a strong dose-exposure relation, a nonlinear least-squares nutrikinetic modeling was further performed on its plasma concentration-time profile from 0 to 7 h post consumption. Compartmental parameter estimates for CNA were determined after fitting of concentration data to several compartmental models on Phoenix WinNonlin (Table S2). The Gauss-Newton algorithm was applied and the final model selection was based on goodness-of-fit comparisons, examination of the residual plots, correlation of the observed and predicted values, and Akaike information criterion. 1/Y2 model yielded the best fit amongst the various weighting schemes used (1/Y, 1/Y², and actual). The final nutrikinetic curve best fit into a one-compartment, schemes used (1/1, 1/1, 1/1) first-order elimination, as described by: $\mathbf{C}(\mathbf{T}) = \frac{\mathbf{D}K_a}{\mathbf{V}\left(K_a - K_e\right)} \left[e^{-K_e\mathbf{T}} - e^{-K_a\mathbf{T}}\right]$


$$C(T) = \frac{DK_a}{V(K_a - K_e)} [e^{-K_e T} - e^{-K_a T}]$$
1)


where C is the plasma concentration, T is time, K_a is the first-order absorption rate, K_c is the first-order elimination rate constant, D is dose, and V is the apparent volume of distribution. Secondary parameters determined from the model included the Cmax, Tmax, AUC0-7 h as well as the terminal half-life.

3. Results

Plasma concentration-time curves of the 11 quantified metabolites across all three doses were presented in Figure 1. The C_{max} , T_{max} and $AUC_{0-7\,h}$ for each metabolite are reported in Table 1. Two phenolic acids, namely 3OH-BA and 4OH-HA were found to be below detection limits. The plasma C_{max} ranged from the low nM to low µM between the metabolites, peaking at various times (T_{max}).

AUC_{0-7 h} for the various phenolic acids were calculated as a measure of the systemic exposure of the metabolites. Scatter plots between the mean normalized AUC₀₋₇ h of each phenolic acid against the TPC of D0C, D1C and D2C meals indicated large inter-individual variations in the dose-exposure associations and also allowed visualization of outliers (Figure S2). Majority of the phenolic acids presented a low dose-exposure correlation after linear regression analysis, apart from CNA. CNA appeared in blood plasma shortly after meal consumption and peaked approximately 1 h post consumption for D1C and D2C. However, for CNA, one particular volunteer was a significant outlier. Even though his results displayed a strong dose-exposure relationship for CNA (Figure S3), this individual had a 15-fold higher AUC_{0-7 h} than the mean CNA concentration at D2C. This individual was therefore excluded from the subsequent analysis of CNA.








Figure 1. Normalized logarithmic plasma concentration-time curves of 11 phenolic acids, specifically (A) benzoic acid (BA); (B) 4-hydroxybenzoic acid (4OH-BA); (C) phenylacetic acid (PAA); (D) 3-hydroxyphenylacetic acid (3OH-PAA); (E) (4OH-PAA); 4-hydroxyphenylacetic acid **(F)** phenylpropanoic acid (G) (PPA); 3-hydroxyphenylpropanoic acid (3OH-PPA); (H) 4-hydroxyphenylpropanoic acid (4OH-PPA), (I) hippuric acid (HA); (J) 3-hydroxyhippuric acid (3OH-HA); and (K)

Table 1. Plasma nutrikinetics of terminal aromatic acid pathway metabolites after consumption of control 0 g (D0C), 6 g (D1C), and 12 g (D2C) of mixed spices. C_{max} , normalized maximum concentration obtained in plasma (nM); T_{max} , time (h) when C_{max} was reached; AUC_{0-7h} , normalized area under the curve over time (nM.h) until 7 h; N.D., not detected. Results are expressed as mean \pm standard deviation (n=20 for D0C and D2C; n=17 for D1C). *One outlier (Figure S3) was omitted from nutrikinetic analysis of cinnamic acid.


Nutrikinetic parameters	C _{max} (nM)			T _{max} (h)			AUC _{0-7 h} (nM.h)		
Polyphenols intake	D0C	D1C	D2C	D0C	D1C	D2C	D0C	D1C	D2C
Benzoic acid derivatives									
Benzoic acid (BA)	114.3 ± 36.7	113.3 ± 33.6	109.0 ± 34.6	5.3 ± 2.2	5.7 ± 2.0	3.8 ± 2.8	347.9 ± 86.8	347.0 ± 107.2	354.7 ± 122.8
3-Hydoxybenzoic acid (3OH-BA)	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
4-Hydroxybenzoic acid (4OH-BA)	13.7 ± 9.9	18.3 ± 12.4	41.5 ± 101.2	3.1 ± 1.7	3.4 ± 2.1	3.5 ± 1.5	36.0 ± 23.3	54.2 ± 34.6	114.1 ± 207.0
Phenylacetic acid derivatives									
Phenylacetic acid (PAA)	433.3 ± 286.9	1019.1 ± 825.9	1001.4 ± 666.2	3.4 ± 2.4	3.6 ± 1.4	3.2 ± 1.3	1742.3 ± 1243.4	4437.2 ± 2974.3	4132.1 ± 2947.1
3-Hydroxyphenylacetic acid (3OH-PAA)	28.1 ± 26.2	27.2 ± 15.8	29.1 ± 20.5	4.9 ± 2.0	4.7 ± 2.6	5.7 ± 1.7	101.0 ± 112.2	105.7 ± 70.0	113.3 ± 90.4
4-Hydroxyphenylacetic acid (4OH-PAA)	565.9 ± 322.3	667.3 ± 304.9	633.4 ± 285.1	4.7 ± 2.0	4.4 ± 2.0	3.8 ± 1.8	2070.7 ± 1453.7	2378.0 ± 1065.8	2166.7 ± 1067.5
Phenylpropanoate derivatives									
Phenylpropanoate acid (PPA)	278.7 ± 322.4	730.7 ± 1224.0	554.4 ± 984.6	2.5 ± 1.8	2.8 ± 2.3	3.0 ±2.2	831.1 ± 783.9	2390.8 ± 4371.0	1859.8 ± 3426.7
3-Hydroxyphenylpropanoic acid (3OH- PPA)	58.9 ± 39.1	83.3 ± 79.5	72.5 ± 48.6	3.6 ± 2.8	4.0 ± 2.8	3.5 ± 2.9	182.2 ± 126.3	283.0 ± 388.2	226.3 ± 176.6
4-Hydroxyphenylpropanoic acid (4OH-PPA)	31.4 ± 25.0	48.6 ± 36.6	81.7 ± 102.2	3.1 ± 2.7	2.6 ± 1.7	3.3 ± 2.0	126.3 ± 115.1	178.0 ± 120.3	260.6 ± 131.7
Hippuric acid derivatives									
Hippuric acid (HA)	1286.2 ± 706.5	1369.2 ± 1167.5	1075.8 ± 615.7	2.4 ± 3.3	3.4 ± 3.2	0.5 ± 0.3	1832.7 ± 1421.5	3224.5 ± 3095.2	3063.1 ± 1795.5
3-Hydroxyhippuric acid (3OH-HA)	26.3 ± 22.5	27.4 ± 19.1	31.3 ± 26.5	3.3 ± 3.1	4.8 ± 2.9	3.8 ± 3.2	70.7 ± 61.6	80.1 ± 68.3	88.4 ± 85.4
4-Hydroxyhippuric acid (4OH-HA)	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
Cinnamic acid derivatives									
Cinnamic acid (CNA)*	2.4 ± 0.7	164.4 ± 47.7	342.0 ± 83.0	2.8 ± 1.9	0.7 ± 0.4	1.4 ± 1.2	8.4 ± 3.4	376.1 ± 104.7	875.7 ± 291.9


210

211

A repeated measures ANOVA showed significant increases in AUC_{0-7 h} of CNA when comparing D0C to D1C to D2C (F(1.109, 16.63) = 75.94, p<0.0001), with post hoc tests using Bonferroni correction revealing significant differences between D0C and D1C, between D0C and D2C, and between D1C and D2C (all p<0.0001). Similarly, significant increases in AUC_{0-7 h} of PAA with the same comparisons (F(1.964, 31.42) = 9.847, p<0.0005), with post hoc tests using Bonferroni correction showing significant differences between D0C and D1C (p<0.001), and between D0C and D2C (p<0.0054). AUC_{0-7 h} of other phenolic acids were not statistically significantly different between various doses, even though there were some indication of increases in some phenolic acids such as 4OH-BA during the curry sessions (D1C and D2C) as compared with the control session.

A closer examination in the nutrikinetics of CNA also revealed the presence of a secondary peak during both D1C and D2C periods at around 3 h (Figure 2A). Regression analysis of CNA AUC_{0-7 h} against the polyphenol amount expressed in GAE showed a strong linear correlation R^2 of 0.8093 (Figure 2B). Compartmental modeling of CNA showed best fit to a no lag time, 1^{st} order absorption, 1^{st} order elimination, 1-compartment model, with average elimination half-life of 0.66 h and T_{max} at 0.96 h (Figure 2C).





	Interventi	C_{max}	T_{max}	AUC	Ke	T _{0.5}
Model	on	(nM)	(h)	(nM.h)	(1/h)	(h)
1st order absorption &	D0C	2.73	3.42	25.41	0.29	2.37
elimination, 1-	D1C	143.95	0.94	346.94	1.07	0.65
compartment, no lag time	D2C	322.55	0.97	846.70	1.04	0.67




Figure 2. (A) Normalized linear plasma concentration against time plots of cinnamic acid. **(B)** Scatter plot and linear regression of normalized area under the curve (AUC) against polyphenol amount expressed in gallic acid equivalent (GAE) of cinnamic acid. **(C)** Nutrikinetic modeling of cinnamic acid, best fitted by a one-compartment model. AUC, normalized area under the curve; C_{max}, normalized maximum concentration obtained in plasma (nM); K_e, elimination rate constant; T_{0.5}, half-life; T_{max}, time (h) when C_{max} is obtained.

4. Discussion

While spices are known to contain high levels of polyphenols, our study is the first to show dose-dependent increases in plasma CNA concentrations in response to increasing doses of mixed spice consumption. In support of our findings, previous studies with other polyphenol rich foods such as wholegrain cereals [23], tea [9], coffee [24] and berries [10,25] have all shown increases in the plasma levels of phenolic acids upon consumption. Thus, our findings confirmed that phenolic acids, particularly CNA, are indeed important systemic metabolites of spices-derived dietary polyphenols.

The blood sampling regime at numerous time points and at regular intervals during a 7-hour postprandial period in this study allowed for a detailed insight on the plasma nutrikinetics of the phenolic acids in relation to the dose-dependent increases in curry intake. We restricted our analyses only to free, unconjugated phenolic acids, without the any prior enzymatic deconjugation. This is because several uncertainties exist regarding the widespread use deconjugating enzymes (such as glucoronidases and sulfatases) in studies exploring bioavailability of polyphenols. Firstly, the deconjugating enzymes may often only partially hydrolyse the relevant phenolic acid conjugates [26,27] which could lead to either overestimation or underestimation of phenolic acids in vivo. Secondly, glucuronidated conjugates can spontaneously undergo deconjugation in vivo after reacting with hydroxyl or sulfhydryl groups to reform free phenolic acids [28]. Finally, it is also known that certain polyphenolic compounds, including phenolic acids, tend to display greater bioactive potencies in their free forms than in their conjugated forms [29,30]. Individual phenolic acids displayed high degree of inter-individual variability in their Cmax and systemic exposure (AUC_{0.7 h}) in response across the 3 doses of curry. This was probably due to the fact that polyphenols are simultaneously metabolized both by the human (host) metabolic pathways as well as by the gut microflora present, which can collectively modify the rate and extent of absorption, distribution and excretion of dietary polyphenols [4].

The inter-individual variation in phenolic acid nutrikinetics was large despite the rigorously controlled study design (Figure 1) and the careful validation of the analytical methods (Table S1). Similar extents of inter-individual variability were also observed in several other dietary intervention studies [31,32]. We postulate that the observed nutrikinetic variability might be a result of variations in host xenobiotic disposition functions including complex oral absorption and hepatic clearance mechanisms as well as variations in gut microbial functions. Presently there are still lapses in our understanding on the roles and the relative contributions of specific bacterial species as well as differences in host single nucleotide polymorphisms (SNPs) towards this variability. Moreover, using integrated systems biology tools, our laboratory previously interrogated the complex roles of gut microbiota on the systemic absorption and disposition of a xenobiotic [33]. Similar approaches can be applied in future studies to validate our postulation on the variable nutrikinetics of polyphenol metabolites.

Hippuric acid (HA) was identified as the most abundant phenolic acid in plasma with a maximum concentration reaching above 1200 nM (Table 1). We observed an initial increase in plasma HA concentration immediately after the mixed spice consumption followed by a dip below baseline followed by further increase again. While this initially appeared idiosyncratic, our results corroborated with the observations of three reports that investigated the nutrikinetics of HA [10,32,34]. We postulate the high baseline concentration of HA was associated with the consumption of non-polyphenol sources of HA prior to the study, given that the 15 h overnight fasting period during this study was shorter than the 22 h half-life of HA [35]. Moreover, the increases in HA after 5-6 h consumption indicate bacterial metabolism in the colon particularly since *in vivo* HA concentration has been previously shown to be associated with gut microbiome content [36]. These findings are certainly important considerations while using HA as a biomarker of total polyphenol intake.

Phenylacetic acids (PAA, 3OH-PAA, and 4OH-PAA) are often present in blood plasma after consumption of polyphenol-rich food sources [32]. While all three phenylacetic acids were detected in our study, only the systemic exposure of PAA was significantly increased after consumption of D1C and D2C meals. PAA is an endogenous product of phenylalanine metabolism circulating at low concentration levels, but is also a well-known gut microbiome metabolite derived from colonic bacterial metabolism of unabsorbed polyphenols [38]. The microbial origin of PAA is also demonstrated when it was found to be excreted in greater amount after germ-free rats were inoculated with fecal microorganisms [39]. The similar increases in plasma PAA concentrations during both D1C and D2C sessions may suggest either rate-limiting steps along the degradation of polyphenols by colonic bacteria, and/or limiting absorption processes by intestinal epithelial cells, possibly indicating saturation even at the lower mixed spice dose (D1C session).

Cinnamaldehyde, the precursor of CNA, is a major constituent in Ceylon cinnamon and other species under the genus *Cinnamomum* [40]. Cinnamaldehyde and its derivatives have gained much interest in recent years for its ability to alleviate diabetic complications *in vivo* [19], and its pharmacology and pharmacokinetics have been extensively reviewed by Zhu *et al.* [41]. Cinnamaldehyde is not stable in the body. It was reported to be partly oxidized to CNA in stomach and intestine [42], and extensively oxidized to CNA after absorption. Given the strong linear correlation between the normalized AUC_{0-7 h} of CNA and the oral doses of mixed spices in our study, CNA represents a robust biomarker of dietary spice consumption. Pharmacokinetic investigation of CNA is currently limited in humans and to our knowledge, there is only one previous report on the nutrikinetic profile of CNA in human [43], who utilized a two-compartment, first-order elimination model. In our study, the assessment of both one- and two-compartment models, together with permutation of other model parameters (Fig S2), showed marginally superior fitting with a one-compartment model, first-order elimination model over other tested models.

The presence of a secondary C_{max} of plasma CNA in both D1C and D2C of mixed spices is an unexpected and novel finding in humans. While this phenomenon was not observed in an i.v. human clinical study [43], similar secondary peaks was observed in rats with p.o. administration of Cinnamomi Ramulus (Cinnamomum cassia) [44]. Several reasons could account for this observation, including enterohepatic recycling, site-specific absorption or delayed gastric emptying. The role of enterohepatic recycling of CNA may be minor, as CNA is primarily eliminated (63%) via oxidation (β-oxidation) and subsequently glycine conjugation to form HA, with a small fraction being glucuronidated only when the liver's capacity for glycine conjugation is exceeded [40]. Site-specific absorption refers to concurrent absorption in the organs such as the stomach, resulting in multiple sites of absorption and secondary peaks in plasma concentration-time profiles. While CNA may be partially absorbed via monocarboxylic acid transporters (MCT) along the entire length of gastrointestinal tract, CNA shows far greater absorption in duodenum, jejunum, cecum and colon relative to the stomach in rats [45]. Lastly, gastric emptying controls the amount of chyme entering the duodenum and is likely to modulate the absorption of xenobiotics with high solubility and permeability such as CNA. Furthermore, some of the ingredients used in our study (coriander, cumin, garlic, and onion) have been shown to reduce gastric transit time [46], and may therefore affect the kinetics of well-absorbed compounds such as CNA to yield multiple peaking. It should be noted that secondary peaks in CNA were only observed in 14 out of 20 participants who took part in our study, which further highlight the inter-individual variability in polyphenol metabolism.

While our study sheds novel insights on the dose-exposure associations between polyphenol rich spice intake and the concentrations of free/unconjugated phenolic acids in plasma there were a few limitations that need to be considered. Apart from measuring the total polyphenol content of the spice containing test meals we did not characterize nor quantify the individual polyphenols present in these meals. This was principally an analytical hurdle for the team, given the lack of

- 336 high-resolution mass spectrometry instruments. Furthermore, the treatment of samples with 337 glucuronidase/sulfatase enzymes would have yielded quantification of total aglycones, although for 338 reasons discussed above we decided against this approach. The study of downstream metabolites of 339 the terminal phenolic acid pathway could potentially be confounded by alternative sources of 340 polyphenols. While the volunteers were asked to avoid polyphenol rich foods for a 72 h prior to 341 study, baseline (0 h) levels of the several metabolites were rather variable, including some having 342 somewhat higher baseline concentrations of certain phenolic acids. This may indicate lower 343 compliance during the 3-day 'run-in' periods for some volunteers, who may have consumed these 344 polyphenol-containing foods due to the omnipresence of polyphenols in a plethora of food options. 345 Challenges such as these are inevitable when conducting dietary intervention trials in a free-living 346 population. Similar challenges are now being dealt with by using stable isotopes of polyphenols to 347 accurately understand nutrikinetics and metabolism of polyphenols [47]. Another limitation to this 348 study was the measurement of plasma samples at regular intervals only for a period of up to 7 hours. 349 While this is common for metabolic studies in nutrition, this approach may have missed out on 350 further changes in phenolic acid concentrations particularly involving gut mediated metabolism 351 beyond the duration measured. Despite these limitations, our study is first dose-response study with
- 355 **Supplementary Materials:** Supplementary materials are available online at

the existing literature of the large inter-individual variability in the metabolism of polyphenols.

mixed spices exploring nutrikinetics of plasma phenolic acids. The strong dose-exposure association

of CNA indicates its potential use as a biomarker of spice intake. We also confirmed findings from

- https://www.preprints.org/manuscript/201806.0410/v1.

 Author Contributions: S. Haldar has designed and conducted this study, S. H. Lee has planned experiments and quantified the metabolites L. L. Tan has quantified the metabolites and performed compartmental
- and quantified the metabolites, J. J. Tan has quantified the metabolites and performed compartmental modeling, S. C. Chia has recruited participants and undertaken the sample collection for the study, C.J. Henry has contributed to the study design and data interpretation, E. C. Y. Chan has supervised the samples analysis. S. Haldar, S. H. Lee and J. J. Tan have written the manuscript. All authors read and approved the manuscript.
- Funding: This project was funded by the Singapore Institute for Clinical Sciences, Agency for Science Technology and Research (A*STAR), Singapore.
- Acknowledgments: Acknowledgement to Dr Yau Wai Ping for the Phoenix WinNonlin software, Ms Susanna Lim for phlebotomy and the volunteers for taking part in this study.
- 366 Conflicts of Interest: The authors declare no conflict of interest.

367 References

352

353

354

- Tapsell, L. C.; Hemphill, I.; Cobiac, L.; Patch, C. S.; Sullivan, D. R.; Fenech, M.; Roodenrys, S.; Keogh, J.
 B.; Clifton, P. M.; Williams, P. G.; Fazio, V. A.; Inge, K. E. Health benefits of herbs and spices: the past,
 the present, the future. *Med. J. Aust.* 2006, 185, S4-24.
- 2. Rothwell, J. A.; Perez-Jimenez, J.; Neveu, V.; Medina-Remón, A.; M'Hiri, N.; García-Lobato, P.; Manach, C.; Knox, C.; Eisner, R.; Wishart, D. S.; Scalbert, A. Phenol-Explorer 3.0: A major update of the Phenol-Explorer database to incorporate data on the effects of food processing on polyphenol content.

 Database 2013, 2013, 1–8, doi:10.1093/database/bat070.
- 375 3. Marín, L.; Miguélez, E. M.; Villar, C. J.; Lombó, F. Bioavailability of dietary polyphenols and gut microbiota metabolism: Antimicrobial properties. *Biomed Res. Int.* **2015**, 2015, doi:10.1155/2015/905215.
- 377 4. Cassidy, A.; Minihane, A. M. The role of metabolism (and the microbiome) in defining the clinical efficacy of dietary flavonoids. *Am. J. Clin. Nutr.* 2017, 105, 10–22.
- van Duynhoven, J.; van Velzen, E. J. J.; Westerhuis, J. A.; Foltz, M.; Jacobs, D. M.; Smilde, A. K.
 Nutrikinetics: Concept, technologies, applications, perspectives. *Trends Food Sci. Technol.* 2012, 26, 4–13.
- 381 6. Crozier, A.; Jaganath, I. B.; Clifford, M. N. Dietary phenolics: chemistry, bioavailability and effects on health. *Nat. Prod. Rep.* **2009**, *26*, 1001, doi:10.1039/b802662a.

- Del Rio, D.; Rodriguez-Mateos, A.; Spencer, J. P. E.; Tognolini, M.; Borges, G.; Crozier, A. Dietary (Poly)phenolics in Human Health: Structures, Bioavailability, and Evidence of Protective Effects Against Chronic Diseases. *Antioxid. Redox Signal.* **2013**, *18*, 1818–1892, doi:10.1089/ars.2012.4581.
- 386 van Duynhoven, J.; Vaughan, E. E.; Jacobs, D. M.; A. Kemperman, R.; van Velzen, E. J. J.; Gross, G.; Roger, L. C.; Possemiers, S.; Smilde, A. K.; Dore, J.; Westerhuis, J. a; Van de Wiele, T. Metabolic fate of polyphenols in the human superorganism. *Proc. Natl. Acad. Sci.* **2011**, *108*, 4531–4538, doi:10.1073/pnas.1000098107.
- Henning, S. M.; Wang, P.; Abgaryan, N.; Vicinanza, R.; de Oliveira, D. M.; Zhang, Y.; Lee, R. P.; Carpenter, C. L.; Aronson, W. J.; Heber, D. Phenolic acid concentrations in plasma and urine from men consuming green or black tea and potential chemopreventive properties for colon cancer. *Mol. Nutr. Food Res.* **2013**, *57*, 483–493, doi:10.1002/mnfr.201200646.
- 394 10. De Ferrars, R. M.; Czank, C.; Zhang, Q.; Botting, N. P.; Kroon, P. A.; Cassidy, A.; Kay, C. D. The pharmacokinetics of anthocyanins and their metabolites in humans. *Br. J. Pharmacol.* **2014**, *171*, 3268–3282, doi:10.1111/bph.12676.
- 397 11. Borges, G.; Mullen, W.; Mullan, A.; Lean, M. E. J.; Roberts, S. A.; Crozier, A. Bioavailability of multiple 398 components following acute ingestion of a polyphenol-rich juice drink. *Mol. Nutr. Food Res.* **2010**, *54*, 399 268–277, doi:10.1002/mnfr.200900611.
- Clifford, M.; van der Hooft, J.; Crozier, A. Human studies on the absorption, distribution, metabolism, and excretion of tea polyphenols. *Am. J. Clin. Nutr.* **2013**, *98*, 1619S–30S, doi:10.3945/ajcn.113.058958.1.
- 402 13. Zamora-Ros, R.; Rothwell, J. A.; Scalbert, A.; Knaze, V.; Romieu, I.; Slimani, N.; Fagherazzi, G.; Perquier, 403 F.; Touillaud, M.; Molina-Montes, E.; Huerta, J. M.; Barricarte, A.; Amiano, P.; Menéndez, V.; Tumino, 404 R.; De Magistris, M. S.; Palli, D.; Ricceri, F.; Sieri, S.; Crowe, F. L.; Khaw, K.-T.; Wareham, N. J.; Grote, V.; 405 Li, K.; Boeing, H.; Förster, J.; Trichopoulou, A.; Benetou, V.; Tsiotas, K.; Bueno-de-Mesquita, H. B.; Ros, 406 M.; Peeters, P. H. M.; Tjønneland, A.; Halkjær, J.; Overvad, K.; Ericson, U.; Wallström, P.; Johansson, I.; 407 Landberg, R.; Weiderpass, E.; Engeset, D.; Skeie, G.; Wark, P.; Riboli, E.; González, C. A. Dietary intakes 408 and food sources of phenolic acids in the European Prospective Investigation into Cancer and Nutrition 409 (EPIC) study. Br. J. Nutr. 2013, 110, doi:10.1017/S0007114513000688.
- 410 14. Lafay, S.; Gil-Izquierdo, A. Bioavailability of phenolic acids. *Phytochem. Rev.* **2008**, *7*, 301–311, doi:10.1007/s11101-007-9077-x.
- 412 15. Srinivasan, K. Role of spices beyond food flavoring: Nutraceuticals with multiple health effects. *Food*413 *Rev. Int.* **2005**, *21*, 167–188, doi:10.1081/FRI-200051872.
- 414 16. Yashin, A.; Yashin, Y.; Xia, X.; Nemzer, B. Antioxidant Activity of Spices and Their Impact on Human Health: A Review. *Antioxidants* **2017**, *6*, 70, doi:10.3390/antiox6030070.
- Haldar, S.; Chia, S. C.; Lee, S. H.; Lim, J.; Leow, M. K.-S.; Chan, E. C. Y.; Henry, C. J. Polyphenol-rich curry made with mixed spices and vegetables benefits glucose homeostasis in Chinese males (Polyspice Study): a dose–response randomized controlled crossover trial. *Eur. J. Nutr.* **2017**, doi:10.1007/s00394-017-1594-9.
- Haldar, S.; Chia, S. C.; Henry, C. J. Polyphenol-rich curry made with mixed spices and vegetables increases postprandial plasma GLP-1 concentration in a dose-dependent manner. *Eur. J. Clin. Nutr.* **2017**, 1, doi:10.1038/s41430-017-0069-7.
- 423 19. Adisakwattana, S. Cinnamic acid and its derivatives: Mechanisms for prevention and management of diabetes and its complications. *Nutrients* 2017, 9.
- 425 20. Johnston, K. L.; Clifford, M. N.; Morgan, L. M. Coffee acutely modifies gastrointestinal hormone

- 426 secretion and glucose tolerance in humans: Glycemic effects of chlorogenic acid and caffeine. Am. J. 427 Clin. Nutr. 2003, 78, 728-733, doi:10.1021/jf980737w.
- 428 21. Crozier, A.; Del Rio, D.; Clifford, M. N. Bioavailability of dietary flavonoids and phenolic compounds. 429 Mol. Aspects Med. 2010, 31, 446–467, doi:10.1016/j.mam.2010.09.007.
- 430 22. Thakare, R.; Chhonker, Y. S.; Gautam, N.; Alamoudi, J. A.; Alnouti, Y. Quantitative analysis of 431 endogenous compounds. J. Pharm. Biomed. Anal. 2016, 128, 426-437.
- 432 23. Bresciani, L.; Scazzina, F.; Leonardi, R.; Dall'Aglio, E.; Newell, M.; Dall'Asta, M.; Melegari, C.; Ray, S.;
- 433 Brighenti, F.; Del Rio, D. Bioavailability and metabolism of phenolic compounds from wholegrain
- 434 wheat and aleurone-rich wheat bread. Mol. Nutr. Food Res. 2016, 60, 2343-2354,
- 435 doi:10.1002/mnfr.201600238.
- 436 24. Renouf, M.; Marmet, C.; Giuffrida, F.; Lepage, M.; Barron, D.; Beaumont, M.; Williamson, G.; Dionisi, F.
- 437 Dose-response plasma appearance of coffee chlorogenic and phenolic acids in adults. Mol. Nutr. Food
- 438 Res. 2014, 58, 301–309, doi:10.1002/mnfr.201300349.
- 439 25. McKay, D. L.; Chen, C. Y. O.; Zampariello, C. A.; Blumberg, J. B. Flavonoids and phenolic acids from
- 440 cranberry juice are bioavailable and bioactive in healthy older adults. Food Chem. 2015, 168, 233-240,
- 441 doi:10.1016/j.foodchem.2014.07.062.
- 442 26. Sinclair, K. A.; Caldwell, J. The formation of β -glucuronidase resistant glucuronides by the
- 443 intramolecular rearrangement of glucuronic acid conjugates at mild alkaline pH. Biochem. Pharmacol.
- 444 1982, 31, 953-957, doi:10.1016/0006-2952(82)90326-4.
- 445 27. Faed, E. M. Properties of acyl glucuronides: Implications for studies of the pharmacokinetics and 446 metabolism of acidic drugs. Drug Metab. Rev. 1984, 15, 1213-1249, doi:10.3109/03602538409033562.
- 447 28. Langguth, H. S.; Benet, L. Z. Acyl Glucuronides Revisited: Is the Glucuronidation Proces a Toxification
- 448 as Well as a Detoxification Mechanism? Drug Metab. Rev. 1992, 24, 5-47, doi:10.3109/03602539208996289.
- 449 29. Piazzon, A.; Vrhovsek, U.; Masuero, D.; Mattivi, F.; Mandoj, F.; Nardini, M. Antioxidant activity of
- 450 phenolic acids and their metabolites: Synthesis and antioxidant properties of the sulfate derivatives of
- 451 ferulic and caffeic acids and of the acyl glucuronide of ferulic acid. J. Agric. Food Chem. 2012, 60, 12312-
- 452 12323, doi:10.1021/jf304076z.
- 453 30. Cren-Olivé, C.; Teissier, E.; Duriez, P.; Rolando, C. Effect of catechin O-methylated metabolites and
- 454 analogues on human LDL oxidation. FreeRadic. Biol. Med. 2003, 34, 850-855,
- 455 doi:10.1016/S0891-5849(02)01433-8.
- 456 31. Cerdá, B.; Tomás-Barberán, F. A.; Espín, J. C. Metabolism of antioxidant and chemopreventive
- 457 ellagitannins from strawberries, raspberries, walnuts, and oak-aged wine in humans: Identification of
- 458 biomarkers and individual variability. J. Agric. Food Chem. 2005, 53, 227-235, doi:10.1021/jf049144d.
- 459 32. Feliciano, R. P.; Boeres, A.; Massacessi, L.; Istas, G.; Ventura, M. R.; Nunes Dos Santos, C.; Heiss, C.;
- 460 Rodriguez-Mateos, A. Identification and quantification of novel cranberry-derived plasma and urinary
- 461 (poly)phenols. Arch. Biochem. Biophys. 2016, 599, 31–41, doi:10.1016/j.abb.2016.01.014.
- 462 33. Yip, L. Y.; Aw, C. C.; Lee, S. H.; Hong, Y. S.; Ku, H. C.; Xu, H.; Mei, J.; Chan, X.; Jing, E.; Cheong, Y.;
- 463 Chng, K. R.; Ng, H. Q.; Nagarajan, N.; Mahendran, R.; Lee, Y. K.; Browne, E. R.; Chun, E.; Chan, Y. The
- 464 Liver-Gut Microbiota Axis Modulates Hepatotoxicity of Tacrine in the Rat. Hepatology 2017, 1-34,
- 465 doi:10.1002/hep.29327.
- 466 34. van Duynhoven, J.; van Der Hooft, J. J.; van Dorsten, F. A.; Peters, S.; Foltz, M.; Gomez-Roldan, V.;
- 467 Vervoort, J.; De Vos, R. C. H.; Jacobs, D. M. Rapid and sustained systemic circulation of conjugated gut
- 468 microbial catabolites after single-dose black tea extract consumption. J. Proteome Res. 2014, 13, 2668-

- 469 2678, doi:10.1021/pr5001253.
- 470 35. Czank, C.; Cassidy, A.; Zhang, Q.; Morrison, D. J.; Preston, T.; Kroon, P. A.; Botting, N. P.; Kay, C. D.
- $471 \hspace{1.5cm} \hbox{Human metabolism and elimination of the anthocyanin , cyanidin-3-glucoside: a 13 C-tracer study 1-}\\$
- 472 3. Am. J. Clin. Nutr. 2013, 97, 995–1003, doi:10.3945/ajcn.112.049247.Am.
- 473 36. Pallister, T.; Jackson, M. A.; Martin, T. C.; Zierer, J.; Jennings, A.; Mohney, R. P.; MacGregor, A.; Steves,
- 474 C. J.; Cassidy, A.; Spector, T. D.; Menni, C. Hippurate as a metabolomic marker of gut microbiome
- diversity: Modulation by diet and relationship to metabolic syndrome. Sci. Rep. 2017, 7, 1-9,
- 476 doi:10.1038/s41598-017-13722-4.
- 477 37. Pereira-Caro, G.; Ludwig, I. A.; Polyviou, T.; Malkova, D.; García, A.; Moreno-Rojas, J. M.; Crozier, A.
- 478 Identification of Plasma and Urinary Metabolites and Catabolites Derived from Orange Juice
- 479 (Poly)phenols: Analysis by High-Performance Liquid Chromatography-High-Resolution Mass
- 480 Spectrometry. J. Agric. Food Chem. 2016, 64, 5724–5735, doi:10.1021/acs.jafc.6b02088.
- $481 \hspace{0.5cm} 38. \hspace{0.5cm} \text{Williamson, G.; Clifford, M. N. Colonic metabolites of berry polyphenols: The missing link to biological} \\$
- 482 activity? Br. J. Nutr. 2010, 104, 48–66, doi:10.1017/S0007114510003946.
- 483 39. Goodwin, B. L.; Ruthven, C. R. J.; Sandler, M. Gut flora and the origin of some urinary aromatic
- 484 phenolic compounds. *Biochem. Pharmacol.* **1994**, 47, 2294–2297, doi:10.1016/0006-2952(94)90268-2.
- 485 40. Hoskins, J. A. The occurrence, metabolism and toxicity of cinnamic acid and related compounds. *J. Appl.*
- 486 *Toxicol.* **1984**, *4*, 283–292, doi:10.1002/jat.2550040602.
- 487 41. Zhu, R.; Liu, H.; Liu, C.; Wang, L.; Ma, R.; Chen, B.; Li, L.; Niu, J.; Fu, M.; Zhang, D.; Gao, S.
- 488 Cinnamaldehyde in diabetes: A review of pharmacology, pharmacokinetics and safety. *Pharmacol. Res.*
- 489 2017, 122, 78–89.
- 490 42. Chen, Y.; Ma, Y.; Ma, W. Pharmacokinetics and bioavailability of cinnamic acid after oral
- 491 administration of Ramulus Cinnamomi in rats. Eur. J. Drug Metab. Pharmacokinet. 2009, 34, 51-56,
- 492 doi:10.1007/BF03191384.
- 493 43. Zhang, J.; Chen, M.; Ju, W.; Liu, S.; Xu, M.; Chu, J.; Wu, T. Liquid chromatograph/tandem mass
- 494 spectrometry assay for the simultaneous determination of chlorogenic acid and cinnamic acid in plasma
- and its application to a pharmacokinetic study. J. Pharm. Biomed. Anal. 2010, 51, 685-690,
- 496 doi:10.1016/j.jpba.2009.09.039.
- 497 44. Ji, B.; Zhao, Y.; Zhang, Q.; Wang, P.; Guan, J.; Rong, R.; Yu, Z. Simultaneous determination of
- 498 cinnamaldehyde, cinnamic acid, and 2-methoxy cinnamic acid in rat whole blood after oral
- 499 administration of volatile oil of Cinnamoni Ramulus by UHPLC-MS/MS: An application for a
- 500 pharmacokinetic study. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2015, 1001, 107–113,
- 501 doi:10.1016/j.jchromb.2015.07.049.
- 502 45. Garrait, G.; Jarrige, J. F.; Blanquet, S.; Beyssac, E.; Cardot, J. M.; Alric, M. Gastrointestinal absorption
- and urinary excretion of trans-cinnamic and p-coumaric acids in rats. J. Agric. Food Chem. 2006, 54, 2944–
- 504 2950, doi:10.1021/jf053169a.
- 505 46. Platel, K.; Srinivasan, K. Digestive stimulant action of spices: A myth or reality? *Indian J. Med. Res.* **2004**,
- 506 119, 167–179.
- 507 47. Achaintre, D.; Buleté, A.; Cren-Olivé, C.; Li, L.; Rinaldi, S.; Scalbert, A. Differential Isotope Labeling of
- 508 38 Dietary Polyphenols and Their Quantification in Urine by Liquid Chromatography Electrospray
- Ionization Tandem Mass Spectrometry. Anal. Chem. 2016, 88, 2637–2644,
- 510 doi:10.1021/acs.analchem.5b03609.